Pharmabiz6h
GSK announces positive results from GLISTEN phase III trial of linerixibat in adults with cholestatic pruritus (relentless itch) associated with PBC
GSK announces positive results from GLISTEN phase III trial of linerixibat in adults with cholestatic pruritus (relentless itch) associated with PBC: London, UK Wednesday, Novembe ...
ENDPOINTS NEWS14h
GSK plots reg­u­la­to­ry fil­ings for PBC itch af­ter pos­i­tive Phase 3 read­out
GSK’s linerixibat helped reduce itch in patients with a rare bile duct disease, meeting its primary endpoint in a late-stage ...
GSK's Investigational Liver Disease Candidate Hits Primary Goal In Late-Stage Study To Treat Relentless Itch In Some Patients
On Tuesday, GSK plc (NYSE:GSK) released the headline results of the GLISTEN global phase 3 trial evaluating linerixibat in ...
MT Newswires on MSN18h
European Equities Close Lower in Tuesday Trading; EU, Euro Area Inflation Rises in October
The European stock markets closed lower in Tuesday trading as The Stoxx Europe fell 0.43%, Germany's DAX was down 0.67%, the FTSE in London was off 0.13%, France's CAC dropped 0.67%, and the Swiss ...
GSK reports positive Phase 3 results for linerixibat in PBC itching
GSK (NYSE:GSK) said a Phase 3 study of its drug linerixibat in the treatment of relentless itching in patients with primary ...
The Pharma Letter20h
Linerixibat shows positive Phase III results in PBC, says GSK
UK pharma major GSK today announced positive headline results of GLISTEN, the ongoing global Phase III clinical trial ...
pharmaphorum22h
GSK drug raises hopes for patients with PBC itch
Interim results from the ongoing GLISTEN trial of linerixibat, GSK's targeted inhibitor of the ileal bile acid transporter ...